Abstract
Maternal combined antiretroviral therapy (cART) successfully prevents HIV mother-to-child transmission but also causes hematological toxicity in the HIV-exposed uninfected (HEU) infant. We performed a single-center prospective observational study. Hematological toxicity during the first year of life (at 3 and 6 weeks, and 3, 6, and 12 months) was compared between HEU infants born in two different time periods: P1 (2000–2001) and P2 (2007–2013). Mother-infant pairs in P1 (n = 55) and P2 (n = 48) mainly differed in maternal ethnic origin, HIV route of transmission, and cART regimens. Anemia and neutropenia were both less common in P2 than P1, albeit not significantly. Earlier normalization of red blood cell mean corpuscular volume levels in P2 infants suggests that current cART maternal regimens and shorter neonatal prophylaxis are less toxic. Leukocyte, lymphocyte, and platelet counts remained within normal values during follow-up, without differences between groups.
Conclusion: New cART regimens have had very little impact on the hematological toxicity in HEU infants.
What is Known: • Antiretroviral drugs during pregnancy and the neonatal period very effectively prevent mother-to-child transmission of HIV infection. • Hematological toxicity has been widely reported among HIV-exposed uninfected children. |
What is New: • In HIV-exposed uninfected children, hematological toxicity is still mainly caused by exposure to zidovudine. • New antiretroviral drugs have very little impact on hematological toxicity among HIV-exposed uninfected children. |
Abbreviations
- ARV:
-
Antiretroviral
- cART:
-
Combined antiretroviral treatment
- DAIDS:
-
Division of acquired immunodeficiency syndrome
- HCV:
-
Hepatitis C virus
- HIV:
-
Human immunodeficiency virus
- MCV:
-
Mean corpuscular volume
- MTCT:
-
Mother-to-child transmission
- ZDV:
-
Zidovudine
References
Bridges EG, Trentesaux C, Lahlil R, Spiga MG, Jeannesson P, Sommadossi JP (1996) 3′-Azido-3′-deoxythymidine inhibits erytroid- specific transcription factors in human erythroid K562 leukemia cells. Eur J Haematol 56:62–67
Bunders MJ, Bekker V, Scherpbier J, Boer K, Godfried M, Kuijpers TW (2005) Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 94:1571–1577
Connor E, Sperling R, Gelber R, Kiselev P, Scott G, O’Sullivan M, VanDyke R, Bey M, Shearer W, Jacobson R et al (1994) Reduction of maternal infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331:1173–1180
Dainiak N, Worthington M, Riordan MA, Kreczko S, Goldman L (1988) 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br J Haematol 69:299–304
Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, Moyo S, Makhema J, Essex M, Lockman S (2011) Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr 56:428–436
Gogu SR, Malter JS, Agrawal KC (1992) Zidovudine-induced blockade of the expression and function of the erythropoietin receptor. Biochem Pharmacol 44:1009–1012
Grupo de expertos de la Secretaría del Plan Nacional sobre el Sida (SPNS), Grupo de Estudio de Sida (GeSIDA)/Sociedad Española de Ginecología y Obstetricia (SEGO) y Sociedad Española de Infectología Pediátrica (SEIP) (2013) Documento de consenso para el seguimiento de la infección por el VIH en relación con la reproducción, embarazo, parto y profilaxis de la transmision vertical del niño expuesto. Available at: http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/DocEmbarazoMarzo2013.pdf. Accessed 3 Dec 2015
Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC (2011) Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. J Am Med Assoc 305:576–584
Lahoz R, Noguera A, Rovira N, Català A, Sánchez E, Jimenez R, Fortuny C (2010) Antiretroviral-related hematologic short-term toxicity in healthy infants. Implications of the new neonatal 4-week zidovudine regimen. Pediatr Infect Dis J 29:376–379
Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S, Enquête Périnatale Française Study Group (2003) Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 17:2053–2061
Lewis LD, Amin S, Civin CI, Letman PS (2004) Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production. Hum Exp Toxicol 23:173–185
National Institute for Allergy and Infectious Disease (NIAID), Division of AIDS. Table for grading the severity of adult and pediatric adverse events, version 2.0 (2014). Available at: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_Grading_Table_v2_NOV2014.pdf. Accessed 3 Dec 2015
Pollack S, Weaver J (1993) Azidothymidine (AZT)-induced siderosis. Am J Hematol 43:230–233
Sollay S, Noguera Julian A, Galli L, Fortuny C, Deyà A, de Martino M, Chiappini E (2015) Strategies for the prevention of mother to child transmission in western countries. Pediatr Infect Dis J 34:S14–S30
Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, Peña-Rosas JP, Bhutta ZA, Ezzati M, Nutrition Impact Model Study Group (Anaemia) (2013) Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995–2011: a systematic analysis of population-representative data. Lancet Glob Health 1:e16–e25
Taron-Brocard C, Le Chenadec J, Faye A, Dollfus C, Goetghebuer T, Gajdos V, Labaume JM, Perilhou A, Mandelbrot L, Blanche J et al (2014) Increased risk of serious bacterial infections due to maternal immunosuppression in HIV-exposed uninfected infants in a European country. Clin Infect Dis 59:1332–1345
Vigilancia Epidemiológica del VIH/SIDA en España. Actualización 30 de Junio de 2014. Instituto de Salud Carlos III, Gobierno de España. Available at: http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/InformeVIHSida_Junio2014.pdf. Accessed 3 Dec 2015
Authors’ contribution
Núria Rovira, Antoni Noguera-Julian, Claudia Fortuny, and Rebeca Lahoz designed the study, collected and analyzed data, debated about conclusions, and wrote the paper. Susana Rives and Ruben Berrueco analyzed and discussed hematological data and reviewed the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was funded by Fundación para la Investigación y Prevención del SIDA en España, award number 240813/09.
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Communicated by David Nadal
Revisions received: 22 March 2016; 23 April 2016
Rights and permissions
About this article
Cite this article
Rovira, N., Noguera-Julian, A., Rives, S. et al. Influence of new antiretrovirals on hematological toxicity in HIV-exposed uninfected infants. Eur J Pediatr 175, 1013–1017 (2016). https://doi.org/10.1007/s00431-016-2730-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-016-2730-x